Inclusion Criteria:

- Able and willing to give written informed consent

- Patients must have a diagnosis of rheumatoid arthritis > 3 months

- Patients must have been receiving methotrexate for 12 weeks prior to screening at
a dose of 10mg - 25 mg weekly.

- Patient must have had an inadequate response after receiving or previously receiving
one (1) but no more than two (2) anti-TNF biologic agents

- Age >/= 18 yrs

- Must have active RA as defined by a DAS28 (Erythrocyte sedimentation rate) score >4.4

- Must have synovitis of at least two joints in one hand/wrist at screening and
baseline

- Must have a negative Pregnancy test and use adequate method of contraception
throughout the trial

- Stable use of Corticosteroids is permitted

- Stable use of Non-steroidal anti-inflammatory drugs is permitted

Exclusion Criteria:

- Functional Class IV

- Pregnancy or breastfeeding

- History of any other inflammatory arthritis

- Sexually active patients who are not using acceptable birth control

- Subjects who have undergone metacarpophalangeal (MCP) arthroplasty or anticipate the
need for such a procedure

- Subjects with a history of cancer in the last five years other than non melanoma skin
cancers

- Subjects who are unable to comply with study and followup procedures

- Subjects who have current or severe symptoms of renal, hepatic, hematologic,
gastrointestinal, pulmonary cardiac, neurologic, or cerebral disease

- Subjects who currently abuse drugs or alcohol

- Subjects with evidence of active or latent bacterial or viral infections at the time
of enrollment

- Subjects who have received live vaccines within 4 months of first dose of study
medication

- Subjects with herpes zoster or cytomegalovirus that resolved less than two months
prior to dosing

- Subjects at risk for tuberculosis (TB). Specifically excluded will be subjects with
a history of active TB within the last 3 years and subjects with latent TB must have
a negative chest X-ray and be started on treatment for at least 28 days prior to
dosing.

- Prior treatment with Rituximab within 12 months

- Prior treatment with more than 2 TNFs

- Intramuscular(IM), Intravenous(IV) Intra-articular (IA) corticosteroids within 28
days prior to baseline

- Subjects who have a metal device affected by MRI (e.g. any type of electronic,
mechanical or magnetic implant, metal slivers, metal objects, cardioverter
defibrillator)

- Subjects who have received any disease modifying agent (DMARD) other than
methotrexate within the past 28 days prior to baseline